基于血液的生物标志物预测中重度创伤性颅脑损伤患者的颅内出血和结局
该研究为前瞻性预后与流行病学研究(证据等级II级),纳入中重度钝性TBI患者(院前GCS评分3-12、收缩压>90 mmHg),测定到急诊时GFAP、UCH-L1和MAP-2。243例患者中55%存在颅内出血,48小时和28天死亡率分别为7%和13%。GFAP联合院前变量较单用院前变量显著改善所有模型的AUC(颅内出血0.82 vs 0.64,48小时死亡率0.84 vs 0.71,28天死亡率0.84 vs 0.66,GOS-E 0.78 vs 0.69,DRS 0.84 vs 0.81,均p<0.001)。作者结论为循环血生物标志物可能改善中重度TBI神经结局和死亡的预测,GFAP最有前景,需在院前环境中进一步评估。
要点
- 中重度TBI患者到急诊时检测GFAP联合院前变量(GCS评分、年龄、性别)较单用院前变量显著改善颅内出血预测(AUC 0.82 vs 0.64,p<0.001)。
- GFAP联合院前变量较单用院前变量显著改善48小时死亡率预测(AUC 0.84 vs 0.71)和28天死亡率预测(AUC 0.84 vs 0.66),均p<0.001。
- GFAP联合院前变量较单用院前变量显著改善6个月GOS-E预测(AUC 0.78 vs 0.69)和DRS预测(AUC 0.84 vs 0.81),均p<0.001。
- 该研究纳入243例中重度钝性TBI患者(院前GCS评分3-12、收缩压>90 mmHg),55%存在颅内出血,48小时和28天死亡率分别为7%和13%。
- 作者认为GFAP是最有前景的标志物,并认为未来需在院前环境中进一步评估。
适用人群与场景
- 纳入中重度钝性TBI患者,院前GCS评分3-12、收缩压>90 mmHg,数据来自院前氨甲环酸治疗TBI试验的安慰剂组。
- 血样于到达急诊科时采集,距受伤时间中位数84分钟。
研究设计与关键结果
- 研究类型为前瞻性预后与流行病学研究,证据等级II级,纳入243例有基线血样的中重度钝性TBI患者;院前GCS评分中位数8(四分位距5-10)。
- 55%患者存在颅内出血,48小时死亡率为7%,28天死亡率为13%;6个月GOS-E≤4分(神经功能不良)占34%,DRS≥7分占24%。
- 将每种生物标志物单独加入院前变量后,大多数预测模型的AUC改善;GFAP联合院前变量较单用院前变量显著改善所有模型:颅内出血AUC 0.82 vs 0.64,48小时死亡率0.84 vs 0.71,28天死亡率0.84 vs 0.66,GOS-E 0.78 vs 0.69,DRS 0.84 vs 0.81,均p<0.001。
证据类型、等级与局限
- 证据类型为前瞻性预后与流行病学研究,原文报告证据等级为II级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为循环血生物标志物可能改善中重度TBI患者神经结局和死亡的预测,优于单用院前特征,GFAP似乎最有前景。
- 作者认为未来需在院前环境中进一步评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Early identification of traumatic intracranial hemorrhage (ICH) has implications for triage and intervention. Blood-based biomarkers were recently approved by the Food and Drug Administration (FDA) for prediction of ICH in patients with mild traumatic brain injury (TBI). We sought to determine if biomarkers measured early after injury improve prediction of mortality and clinical/radiologic outcomes compared with Glasgow Coma Scale (GCS) alone in patients with moderate or severe TBI (MS-TBI).
METHODS: We measured glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCH-L1), and microtubule-associated protein-2 (MAP-2) on arrival to the emergency department (ED) in patients with blunt TBI enrolled in the placebo arm of the Prehospital TXA for TBI Trial (prehospital GCS score, 3-12; SPB, > 90). Biomarkers were modeled individually and together with prehospital predictor variables [PH] (GCS score, age, sex). Data were divided into a training data set and test data set for model derivation and evaluation. Models were evaluated for prediction of ICH, mass lesion, 48-hour and 28-day mortality, and 6-month Glasgow Outcome Scale-Extended (GOS-E) and Disability Rating Scale (DRS). Area under the curve (AUC) was evaluated in test data for PH alone, PH + individual biomarkers, and PH + three biomarkers.
RESULTS: Of 243 patients with baseline samples (obtained a median of 84 minutes after injury), prehospital GCS score was 8 (interquartile range, 5-10), 55% had ICH, and 48-hour and 28-day mortality were 7% and 13%, respectively. Poor neurologic outcome at 6 months was observed in 34% based on GOS-E of 4 or less, and 24% based on DRS greater than or equal to7. Addition of each biomarker to PH improved AUC in the majority of predictive models. GFAP+PH compared with PH alone significantly improved AUC in all models (ICH, 0.82 vs. 0.64; 48-hour mortality, 0.84 vs. 0.71; 28-day mortality, 0.84 vs. 0.66; GOS-E, 0.78 vs. 0.69; DRS, 0.84 vs. 0.81, all p < 0.001).
CONCLUSION: Circulating blood-based biomarkers may improve prediction of neurological outcomes and mortality in patients with MS-TBI over prehospital characteristics alone. Glial fibrillary acidic protein appears to be the most promising. Future evaluation in the prehospital setting is warranted.
LEVEL OF EVIDENCE: Prospective, Prognostic and Epidemiological, level II.
参考来源
- Anderson TN, Hwang J, Munar M, et al. Blood-based biomarkers for prediction of intracranial hemorrhage and outcome in patients with moderate or severe traumatic brain injury. J Trauma Acute Care Surg. 2020. PMID: 32251265. doi:10.1097/TA.0000000000002706
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。